Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Treatment of Parkinson disease with diet-induced hyperketonemia: a feasibility study.

Vanitallie TB, Nonas C, Di Rocco A, Boyar K, Hyams K, Heymsfield SB.

Neurology. 2005 Feb 22;64(4):728-30.

PMID:
15728303
2.

Treatment of Parkinson disease with diet-induced hyperketonemia: a feasibility study.

Jabre MG, Bejjani BP.

Neurology. 2006 Feb 28;66(4):617; author reply 617. No abstract available.

PMID:
16505339
3.

Ketones: metabolism's ugly duckling.

VanItallie TB, Nufert TH.

Nutr Rev. 2003 Oct;61(10):327-41. Review.

PMID:
14604265
4.

The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies.

Leentjens AF, Koester J, Fruh B, Shephard DT, Barone P, Houben JJ.

Clin Ther. 2009 Jan;31(1):89-98. doi: 10.1016/j.clinthera.2009.01.012. Erratum in: Clin Ther. 2009 Mar;31(3):677.

PMID:
19243709
5.

Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease.

Storch A, Jost WH, Vieregge P, Spiegel J, Greulich W, Durner J, Müller T, Kupsch A, Henningsen H, Oertel WH, Fuchs G, Kuhn W, Niklowitz P, Koch R, Herting B, Reichmann H; German Coenzyme Q(10) Study Group.

Arch Neurol. 2007 Jul;64(7):938-44. Epub 2007 May 14.

PMID:
17502459
6.

Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain.

Devi L, Raghavendran V, Prabhu BM, Avadhani NG, Anandatheerthavarada HK.

J Biol Chem. 2008 Apr 4;283(14):9089-100. doi: 10.1074/jbc.M710012200. Epub 2008 Feb 1.

7.

Diets affecting treatment of parkinsonism with levodopa.

Gillespie NG, Mena I, Cotzias GC, Bell MA.

J Am Diet Assoc. 1973 May;62(5):525-8. No abstract available.

PMID:
4572702
8.

Long-duration response to levodopa in patients with advanced Parkinson disease treated with subthalamic deep brain stimulation.

Wider C, Russmann H, Villemure JG, Robert B, Bogousslavsky J, Burkhard PR, Vingerhoets FJ.

Arch Neurol. 2006 Jul;63(7):951-5.

PMID:
16831963
9.

Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study.

Rascol O, Dubois B, Caldas AC, Senn S, Del Signore S, Lees A; Parkinson REGAIN Study Group.

Mov Disord. 2006 Dec;21(12):2110-5.

PMID:
17013922
10.

Foot-tapping rate as an objective outcome measure for Parkinson disease clinical trials.

Gunzler SA, Pavel M, Koudelka C, Carlson NE, Nutt JG.

Clin Neuropharmacol. 2009 Mar-Apr;32(2):97-102. doi: 10.1097/WNF.0B013E3181684C22.

PMID:
18978495
11.

Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.

Talati R, Baker WL, Patel AA, Reinhart K, Coleman CI.

Int J Clin Pract. 2009 Apr;63(4):613-23. doi: 10.1111/j.1742-1241.2009.02027.x. Epub 2009 Feb 16.

PMID:
19222614
12.
13.

Pramipexole in levodopa-treated Parkinson disease patients of African, Asian, and Hispanic heritage.

Parkinson Study Group.

Clin Neuropharmacol. 2007 Mar-Apr;30(2):72-85.

PMID:
17414939
14.

Effect of centrophenoxine against rotenone-induced oxidative stress in an animal model of Parkinson's disease.

Verma R, Nehru B.

Neurochem Int. 2009 Nov;55(6):369-75. doi: 10.1016/j.neuint.2009.04.001. Epub 2009 Apr 16.

PMID:
19375462
15.

Mitochondrial complex I, II/III, and IV activities in familial and sporadic Parkinson's disease.

Hanagasi HA, Ayribas D, Baysal K, Emre M.

Int J Neurosci. 2005 Apr;115(4):479-93.

PMID:
15809215
16.

Subthalamic nucleus stimulation in Parkinson's disease patients intolerant to levodopa.

Lyons KE, Davis JT, Pahwa R.

Stereotact Funct Neurosurg. 2007;85(4):169-74. Epub 2007 Jan 26.

PMID:
17259749
17.
18.

Minimal clinically important change on the unified Parkinson's disease rating scale.

Schrag A, Sampaio C, Counsell N, Poewe W.

Mov Disord. 2006 Aug;21(8):1200-7.

PMID:
16673410
19.

Depression in Parkinson's disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation.

da Silva TM, Munhoz RP, Alvarez C, Naliwaiko K, Kiss A, Andreatini R, Ferraz AC.

J Affect Disord. 2008 Dec;111(2-3):351-9. doi: 10.1016/j.jad.2008.03.008. Epub 2008 May 15.

PMID:
18485485
20.

The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.

Castro-Caldas A, Delwaide P, Jost W, Merello M, Williams A, Lamberti P, Aguilar M, Del Signore S, Cesaro P; Parkinson-Control Study Group.

Mov Disord. 2006 Apr;21(4):500-9.

PMID:
16267842

Supplemental Content

Support Center